{
    "organizations": [],
    "uuid": "705cbe1f3f1939eb7f19f20aaacabf53331d87fb",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ligand-pharma-and-glenmark-pharma/brief-ligand-pharma-and-glenmark-pharma-enter-into-license-agreement-idUSFWN1P60LP",
    "ord_in_thread": 0,
    "title": "BRIEF-Ligand Pharma And Glenmark Pharma Enter Into License Agreement",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 11, 2018 / 2:08 PM / Updated 11 minutes ago BRIEF-Ligand Pharma And Glenmark Pharma Enter Into License Agreement Reuters Staff \nJan 11 (Reuters) - Ligand Pharmaceuticals Inc: \n* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH GLENMARK PHARMACEUTICALS \n* LIGAND PHARMACEUTICALS - ‍ UNDER LICENSE, GLENMARK WILL BE ABLE TO USE FULL OMNIAB PLATFORM TO DISCOVER FULLY HUMAN MONO- AND MULTISPECIFIC ANTIBODIES​ \n* LIGAND PHARMACEUTICALS INC - ‍GLENMARK WILL BE RESPONSIBLE FOR ALL COSTS RELATED TO PROGRAMS​ \n* LIGAND - ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, REGULATORY MILESTONE PAYMENTS, AMONG OTHERS, FOR PRODUCTS INCORPORATING OMNIAB ANTIBODY​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-11T16:06:00.000+02:00",
    "crawled": "2018-01-11T16:22:51.019+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "pharma",
        "glenmark",
        "pharma",
        "enter",
        "license",
        "agreement",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "ligand",
        "pharmaceutical",
        "inc",
        "ligand",
        "enters",
        "worldwide",
        "platform",
        "license",
        "agreement",
        "glenmark",
        "pharmaceutical",
        "ligand",
        "pharmaceutical",
        "license",
        "glenmark",
        "able",
        "use",
        "full",
        "omniab",
        "platform",
        "discover",
        "fully",
        "human",
        "multispecific",
        "ligand",
        "pharmaceutical",
        "inc",
        "responsible",
        "cost",
        "related",
        "ligand",
        "eligible",
        "receive",
        "annual",
        "platform",
        "access",
        "payment",
        "regulatory",
        "milestone",
        "payment",
        "among",
        "others",
        "product",
        "incorporating",
        "omniab",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}